KIORA PHARMACEUTICALS INC 8-K

What Happened

• Kiora Pharmaceuticals, Inc. (KPRX) filed an 8-K on June 11, 2026 reporting results of its June 10, 2026 annual meeting of stockholders. Stockholders elected three Class II directors—Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.—each for a three-year term ending in 2029.
• The company also received non-binding shareholder approval of named executive officer compensation, ratified Haskell & White LLP as its independent registered public accounting firm for the 2026 fiscal year, and approved an amendment to the 2024 Equity Incentive Plan to add 1,500,000 shares available for issuance. The amended plan is filed as Exhibit 10.1 to the 8-K and the proxy statement describing the plan changes was filed April 30, 2026.

Key Details

• Equity plan increase: 1,500,000 additional shares authorized under the 2024 Equity Incentive Plan (Plan Amendment approved June 10, 2026).
• Director elections (Class II, term to annual meeting 2029):
  • Lisa Walters-Hoffert: 1,037,950 votes for; 7,719 withheld; 1,320,660 broker non-votes.
  • Aron Shapiro: 1,030,543 votes for; 15,126 withheld; 1,320,660 broker non-votes.
  • Praveen Tyle, Ph.D.: 1,029,403 votes for; 16,266 withheld; 1,320,660 broker non-votes.
• Executive pay (advisory): Approved non-bindingly—1,019,325 for; 21,670 against; 4,674 abstentions; 1,320,660 broker non-votes.
• Auditor ratification: Haskell & White LLP ratified—2,358,943 for; 5,403 against; 1,983 abstained (no broker non-votes).

Why It Matters

• The 1.5 million-share increase to the equity incentive plan gives the company more shares to grant to employees, directors or consultants under stock-based compensation programs. If and when granted and issued, these shares could dilute existing shareholders; the filing does not state when or how many of the new shares will be issued.
• Election of the three directors and ratification of the auditor are governance items that maintain board continuity and the company’s auditing relationship. The advisory approval of executive compensation indicates shareholder support for the company’s pay practices as disclosed in the proxy.
• Investors tracking potential dilution, executive incentives, or governance changes should review the amended 2024 Equity Incentive Plan (Exhibit 10.1) and the company’s April 30, 2026 proxy statement for full details.